Article

Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers.

Infectious Disease Division, Massachusetts General Hospital, Boston, MA 02114. .
Journal of Virology (Impact Factor: 4.65). 09/2011; 85(18):9646-50. DOI: 10.1128/JVI.05327-11
Source: PubMed

ABSTRACT Elite controllers spontaneously maintain undetectable levels of HIV-1 replication for reasons that remain unclear. Here, we show that in elite controllers, direct ex vivo infection of purified CD4 T cells without prior in vitro activation results in disproportionately low levels of integrated HIV-1 DNA relative to the quantity of reverse transcripts, while the levels of two-long terminal repeat (2-LTR) circles were excessively elevated relative to those of integrated HIV-1 DNA. This indicates that chromosomal HIV-1 integration is inhibited in ex vivo-infected CD4 T cells from elite controllers. This defect in HIV-1 integration was unrelated to p21, a host protein that can restrict early HIV-1 replication steps, and was not visible following infection of in vitro-activated CD4 T cells from elite controllers. These data contribute to increasing evidence that intrinsic inhibition of specific HIV-1 replication steps plays an important role in the ability of elite controllers to maintain undetectable viral loads.

Download full-text

Full-text

Available from: Xu G. Yu, Jan 15, 2014
1 Follower
 · 
125 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The December 2011 5th International Workshop on HIV Persistence during Therapy addressed the issue of HIV persistence among 210 scientists from 10 countries involved in the study of HIV reservoirs and the search of an HIV cure. High quality abstracts were selected and discussed as oral or poster presentations. The aim of this review is to distribute the scientific highlights of this workshop outside the group as analyzed and represented by experts in retrovirology, immunology and clinical research.
    AIDS Research and Therapy 03/2012; 9(1):7. DOI:10.1186/1742-6405-9-7 · 1.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: True long-term nonprogressors (LTNP) / elite controllers (EC) maintain durable control over HIV replication without antiretroviral therapy. Herein we describe four unique individuals who were distinct from conventional LTNP/EC in that they had extraordinarily low HIV burdens and comparatively weak immune responses. As a group, typical LTNP/EC have unequivocally reactive HIV-1 Western blots, viral loads below the lower threshold of clinical assays, low levels of persistent viral reservoirs, an overrepresentation of protective HLA alleles and robust HIV-specific CD8(+) T-cell responses. The four unique cases were distinguished from typical LTNP/EC based on weakly reactive Western blots, undetectable plasma viremia by a single copy assay, extremely low to undetectable HIV DNA levels and difficult to isolate replication-competent virus. All four had at least one protective HLA allele and CD8(+) T-cell responses that were disproportionately high for the low antigen levels, but comparatively lower than those of typical LTNP/EC. These unique individuals exhibit extraordinary suppression over HIV replication and, therefore, higher-level control than has been demonstrated in previous studies of LTNP/EC. Additional insight into the full spectrum of immune-mediated suppression over HIV replication may enhance our understanding of the associated mechanisms, which should inform the design of efficacious HIV vaccines and immunotherapies
    Blood 04/2012; 119(20). DOI:10.1182/blood-2011-10-381996 · 10.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Integration of the viral genome into host cell chromatin is a pivotal and unique step in the replication cycle of retroviruses, including HIV. Inhibiting HIV replication by specifically blocking the viral integrase enzyme that mediates this step is an obvious and attractive therapeutic strategy. After concerted efforts, the first viable integrase inhibitors were developed in the early 2000s, ultimately leading to the clinical licensure of the first integrase strand transfer inhibitor, raltegravir. Similarly structured compounds and derivative second generation integrase strand transfer inhibitors, such as elvitegravir and dolutegravir, are now in various stages of clinical development. Furthermore, other mechanisms aimed at the inhibition of viral integration are being explored in numerous preclinical studies, which include inhibition of 3' processing and chromatin targeting. The development of new clinically useful compounds will be aided by the characterization of the retroviral intasome crystal structure. This review considers the history of the clinical development of HIV integrase inhibitors, the development of antiviral drug resistance and the need for new antiviral compounds.
    BMC Medicine 04/2012; 10:34. DOI:10.1186/1741-7015-10-34 · 7.28 Impact Factor